We came across a bullish thesis on Ultragenyx Pharmaceutical Inc. on HalfBakedInnovations’s Substack by Biotech Distilled. In ...

AbbVie expects these two drugs to generate more than $31 billion in sales in 2026 — about $0.5 billion above its long-term ...

We are thrilled to welcome Elaine to Artiva’s board at such an important time for the company,” said Fred Aslan, M.D., president and chief executive officer of Artiva Biotherapeutics. “Elaine brings ...

AbbVie recently reported record 2025 results and outlined a stronger 2026 outlook, while advancing key immunology assets and ...

AbbVie leads today's top analyst picks after beating Q4 estimates, while RTX and IBM also draw attention for strong results and growth drivers.

ABBV stock declines since it announced earnings results on Feb. 4. Skyrizi and Rinvoq fuel growth, offsetting Humira erosion.

The global pharmaceutical market, now valued at roughly $1.7 trillion, continues to expand. With nearly $4.9 trillion spent annually on healthcare in the U.S. alone—half of the worldwide ...

The portfolio continues to invest in companies we believe are strong and improving and have improvement that is sustainable.

ABBV sees 2026 revenues rising to $67B as Rinvoq and Skyrizi drive growth, with neuroscience gains offsetting Humira erosion ...

OpenAI's newest $8 ChatGPT Go subscription, which launched in January for US users, will show ads. If you want to avoid ads without paying, you can opt out, but it'll limit the number of ...

Were you ready for some non-football consumerism? Ready or not, the Super Bowl’s annual blitz of commercials landed before and during the Seattle Seahawks and New England Patriots defense-first ...

Add Yahoo as a preferred source to see more of our stories on Google. Lay's, Pepsi, Dunkin', and Michelob Ultra rounded out the top five ads on the USA Today Ad Meter. - In 2026, Americans want ...